Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

27.05.22	Biotech Stocks Facing FDA Decision In June 2022 (RTTNews)
23.05.22	FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis (RTTNews)
20.05.22	Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis (GlobeNewswire)
16.05.22	Sanofi : Sarclisa Combination Provides Unprecedented Median PFS In Relapsed Multiple Myeloma (RTTNews)
15.05.22	Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy (GlobeNewswire)
11.05.22	Press Release: New nirsevimab data analyses reinforce efficacy against RSV (GlobeNewswire)
04.05.22	Press Release: Foundation S: Sanofi’s new philanthropic spearhead (GlobeNewswire)
03.05.22	Press Release: Annual General Meeting of May 3, 2022 (GlobeNewswire)
28.04.22	Sanofi Q1 Profit Climbs; Backs FY22 Business EPS Growth View - Quick Facts (RTTNews)
26.04.22	Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence (GlobeNewswire)
14.04.22	Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine (GlobeNewswire)
07.04.22	Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma (RTTNews)
07.04.22	Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation (GlobeNewswire)
04.04.22	Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board (GlobeNewswire)
04.04.22	Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE (RTTNews)
04.04.22	Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis (GlobeNewswire)
01.04.22	Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022 (GlobeNewswire)
31.03.22	Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines (GlobeNewswire)
30.03.22	Press Release: Availability of the Q1 2022 Memorandum for modelling purposes (GlobeNewswire)
29.03.22	Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets (GlobeNewswire)
29.03.22	Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver (GlobeNewswire)
28.03.22	Sanofi-aventis Reports Expanded Approval Of Dupixent In Canada To Include Children Aged Six To 11 (RTTNews)
28.03.22	Sanofi: Xenpozyme Gets Marketing Authorization In Japan For ASMD (RTTNews)
28.03.22	Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency (GlobeNewswire)
26.03.22	Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis (GlobeNewswire)
18.03.22	Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris (GlobeNewswire)
16.03.22	Seagen, Sanofi In Deal To Develop And Commercialize Multiple Novel Antibody-Drug Conjugates (RTTNews)
16.03.22	Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates (GlobeNewswire)
15.03.22	Sanofi: Blackstone Life To Provide Investment To Advance Subcutaneous Dosage Form For Sarclisa (RTTNews)
15.03.22	Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma (GlobeNewswire)
14.03.22	Sanofi: Amcenestrant Phase 2 Trial Fails To Meet Primary Goal In ER+/HER2- Breast Cancer (RTTNews)
14.03.22	Sanofi : Phase 2 Trial Of Amcenestrant On Metastatic Breast Cancer Fails To Meet Primary Endpoint (RTTNews)
14.03.22	Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer (GlobeNewswire)
09.03.22	Sanofi: Efanesoctocog Alfa Meets Primary, Key Secondary Endpoints In Phase 3 Study In Hemophilia A (RTTNews)
09.03.22	Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment (GlobeNewswire)
08.03.22	Sanofi recognized by S&P as one of the most sustainability-committed companies (GlobeNewswire)
03.03.22	Nirsevimab significantly protected infants against RSV disease in Phase 3 trial (GlobeNewswire)
26.02.22	Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis (GlobeNewswire)
26.02.22	Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria (GlobeNewswire)
23.02.22	Sanofi, GSK To Seek Authorization For COVID-19 Vaccine Based On Data From Booster & Efficacy Trials (RTTNews)
23.02.22	Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine (GlobeNewswire)
22.02.22	Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors (GlobeNewswire)
18.02.22	Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility (RTTNews)
18.02.22	Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program (GlobeNewswire)
10.02.22	Regeneron, Sanofi: FDA Accepts Dupixent Priority Review In Children With Atopic Dermatitis (RTTNews)
10.02.22	FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (GlobeNewswire)
09.02.22	Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD (GlobeNewswire)
05.02.22	Sanofi : FDA Approves Enjaymo, First Treatment For Use In Patients With Cold Agglutinin Disease (RTTNews)
04.02.22	FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease (GlobeNewswire)
04.02.22	Sanofi Q4 Results Rise; Sees Growth In FY22 Business EPS (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:17		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

17:58

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone